Y0000709
Oxitropium bromide
European Pharmacopoeia (EP) Reference Standard
Sign Into View Organizational & Contract Pricing
All Photos(1)
Select a Size
Change View
50 MG
$236.00
About This Item
Empirical Formula (Hill Notation):
C19H26BrNO4
CAS Number:
Molecular Weight:
412.32
UNSPSC Code:
41116107
NACRES:
NA.24
Recommended Products
grade
pharmaceutical primary standard
API family
oxitropium
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
SMILES string
[Br-].[N+]1(C2C3OC3C1CC(C2)OC(=O)C(CO)c4ccccc4)(CC)C
InChI
1S/C19H26NO4.BrH/c1-3-20(2)15-9-13(10-16(20)18-17(15)24-18)23-19(22)14(11-21)12-7-5-4-6-8-12;/h4-8,13-18,21H,3,9-11H2,1-2H3;1H/q+1;/p-1
InChI key
LCELQERNWLBPSY-UHFFFAOYSA-M
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Oxitropium bromide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
related product
Product No.
Description
Pricing
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.
If you need assistance, please contact Customer Support.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Luciano Corda et al.
Respiration; international review of thoracic diseases, 76(1), 61-68 (2008-03-06)
No consistent data are available regarding the effect of inhaled corticosteroids (ICS) in alpha(1)-antitrypsin-deficiency (AATD)-related COPD. Recent data report inflammatory effects of the polymers of alpha(1)-antitrypsin on the peripheral lung. The aim of this study was to assess the effectiveness
Katsuhisa Ikeda et al.
Acta oto-laryngologica, 128(12), 1337-1341 (2008-07-09)
The underlying pathophysiological mechanisms of the posterior nasal nerve (PNN) resection involved the suppression of the secretogogue motor and the inhibition of neurogenic inflammation induced by parasympathetic and sensory denervation. The study was designed to clarify the underlying mechanisms of
V Bellia et al.
Respiratory medicine, 96(11), 881-889 (2002-11-07)
We compare the efficacy including spirometry, peak expiratory flow (PEFR) and quality of life and safety of an 8-week treatment with inhaled oxitropium, theophylline or their combination in patients with mild-to-severe chronic obstructive pulmonary disease (COPD). We conducted a multicentre
Željko Skoko et al.
Journal of the American Chemical Society, 132(40), 14191-14202 (2010-09-24)
The anticholinergic agent oxitropium bromide possesses rich crystal chemistry, most remarkably exhibiting a strong thermosalient effect ("jumping crystal" effect), a mechanical property with potential applications in organic-based actuators. The thermosalient effect, manifested in forceful jumps of up to several centimeters
Hiroshi Kanazawa et al.
Chest, 125(4), 1368-1371 (2004-04-14)
The interaction between chronic hepatitis C virus (HCV) infection and bronchial asthma is of considerable interest. This study was designed to examine whether differences in airway responses to an inhaled anticholinergic agent exist between asthmatic patients with and without active
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service
